Saturday, January 17, 2015

The Eventful Liposomal Formulation Procedural

By Kristen Baird


Progress in research and development in the medical field is always a good indicator. Hope is bestowed when such advances take place as they signal for better and new ways to deal with diseases. Among such progress is the advent of liposomal formulation in aiding in quicker and better ways of dealing with several ailments.

The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.

The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.

The main advantage of using liposomes comes from its core structure. The procedure of formation is key to this. They are formed when a specific heat level is exposed to phospholipids immersed in water. This provides the right atmosphere for formation of liposomes. The physiochemical composition should then be deduced so as to enable the liposome act as an appropriate carrier for an appropriate drug - given its composition to avoid any reactions.

When such discoveries are made, researchers are eager to push it so as to find out if the new discovery can lead to better drugs. IN this case it did. An anthracycline drug known as Doxorubicin was developed to help control the spread of cancer. This is achieved by injecting stains of base DNA and RNA into the malignant cells. The enzyme topoisomerase is also injected at a later stage. These procedures inhibit replication of the cells actively controlling their growth.

Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.

There has been considerable progress in the development of vaccines for diseases which do not have known cures. Such include hepatitis A, which now has a vaccine, Epaxal, under development. Inflexal V is a vaccine developed for several types of influenza especially in children. A vaccine for cancer known as Stimuvax is also in the offering.

The use of liposomes as a carrier for dietary supplements is a newer idea that I undergoing further research. The idea is to use the same technique as the currently successful targeted drug delivery to deliver various supplements taken orally to specific areas in the body. This is however still undergoing research and testing. The use of liposomes in creation of various drugs and vaccines has led to a huge leap in terms of drug research and development. The process of the formulation has thus been lauded as wielding enormous potential for development of better medical solutions for a lot of persistent medical conditions.




About the Author:



0 comments:

Post a Comment